NuVasive (NUVA)
has strung together four quarters of above-market growth, but investors
remain skeptical as to just how quickly new management can get this
business back on a better path. Progress on operating margin expansion
has been frustratingly inconsistent, though management has made it clear
that 2019 is a re-investment year, and it will take time for the
company to recover from the mistakes of the former management team,
including supporting/ignoring the wrong product development
opportunities.
The shares look undervalued to me on
both cash flow and revenue growth, and I believe the company is on its
way toward fixing/resolving a lot of the issues that have caused
problems over the last few years.
Read more here:
NuVasive Is On A Better Path, But Remains A 'Show Me' Story
No comments:
Post a Comment